GLP‑1 plus SGLT2 in fatty liver disease
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
Combination therapy is where metabolic medicine is heading.
In real clinics, many patients with type 2 diabetes end up on a GLP‑1 drug and an SGLT2 inhibitor together. The logic is straightforward: the drugs work through different pathways, and each has a track record of cardiometabolic benefit. The evidence question is harder: does the combination translate into fewer serious outcomes, especially for people with fatty liver disease?
A new study in Hepatology uses U.S. insurance claims data to emulate a “target trial” and asks a practical question: among adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes, is GLP‑1 + SGLT2 therapy associated with fewer major liver and cardiovascular events than either drug class alone?
First, what MASLD means
MASLD is the newer umbrella term for what many people still call “fatty liver disease” in the context of metabolic risk factors. It’s common, it often travels with diabetes and obesity, and in a subset of people it can progress to cirrhosis and liver cancer.
Because MASLD is tied up with cardiovascular risk, it’s not just a liver story. It’s a whole-body risk story.
What the authors did
This is not a randomized trial. It’s a target trial emulation, meaning the authors used observational data (here, the U.S. MarketScan database) and tried to design the analysis to resemble a trial as much as possible.
They built propensity score-matched cohorts comparing:
- people on the combination vs people on a GLP‑1 drug alone
- people on the combination vs people on an SGLT2 inhibitor alone
They then ran time-to-event models in an “on-treatment” design.
What they found (short follow-up, big signals)
In this dataset, the combination was associated with lower risk of both:
- major adverse liver outcomes
- major adverse cardiovascular events
compared with either drug class alone.
The reported hazard ratios are directionally strong. But it’s also important to notice the median follow-up was only around six months. That’s long enough to pick up differences in clinical events in a large dataset, but it’s not long enough to answer durability questions, and it raises the odds that selection effects matter (for example, who is chosen for combination therapy, and who can stay on it).
How to read this without overreading it
The most useful interpretation is:
- It supports the idea that “stacking” these drug classes may be more than just additive effects on weight and glucose.
- It nudges the field toward measuring hard outcomes in MASLD, not only liver fat on imaging.
The least useful interpretation is:
- “Therefore everyone with fatty liver should be on the combo.”
This study can’t establish that. Claims-based observational studies can be extremely informative, but they can’t fully remove residual confounding or guarantee that outcomes were captured uniformly.
What would change confidence next
Two things would tighten the story:
- Longer follow-up with clear, pre-specified liver outcomes (progression to cirrhosis, decompensation, liver cancer).
- Better characterization of baseline MASLD severity (claims data is blunt here).
If future studies keep pointing the same direction, we’ll have something rare in MASLD research: evidence that a pharmacologic strategy changes real outcomes, not just labs.
Further reading
- GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes (PubMed): https://pubmed.ncbi.nlm.nih.gov/42029657/